0001209191-20-002167.txt : 20200106 0001209191-20-002167.hdr.sgml : 20200106 20200106202921 ACCESSION NUMBER: 0001209191-20-002167 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200102 FILED AS OF DATE: 20200106 DATE AS OF CHANGE: 20200106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haddadin Yezan Munther CENTRAL INDEX KEY: 0001718004 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 20511844 MAIL ADDRESS: STREET 1: ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA STREET 2: 4TH FLOOR, PO BOX 142904 CITY: AMMAN STATE: M2 ZIP: 11844 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-02 0 0001649989 Outlook Therapeutics, Inc. OTLK 0001718004 Haddadin Yezan Munther C/O OUTLOOK THERAPEUTICS, INC. 7 CLARKE DRIVE CRANBURY NJ 08512 1 0 0 0 Stock Option (Right to Buy) 0.875 2020-01-02 4 A 0 5980 0.9853 A 2030-01-02 Common Stock 5980 5980 D The options were granted under the 2015 Plan in lieu of $5,892.86 cash fees payable under the Issuers's non-employee Director compensation program and vest in three equal quarterly installments on the last day of each remaining fiscal quarter (3/31, 6/30 and 9/30) such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. /s/ Lawrence Kenyon, Attorney-in-Fact 2020-01-06